Real-World tracking of cancer drug combo for rare mutations

NCT ID NCT06262919

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing how well the approved drugs dabrafenib and trametinib work and how safe they are for patients with advanced solid tumors that have a specific BRAF V600E mutation. It will follow about 110 adult and pediatric patients in real-world medical settings, tracking tumor response and side effects, especially growth and development in children. The goal is to gather long-term safety and effectiveness data after the drugs have been approved for these cancer types.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION-POSITIVE UNRESECTABLE ADVANCED OR RECURRENT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
COMPLETED

Nagakute, Aichi-ken, 480-1195, Japan
Novartis Investigative Site
RECRUITING

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
COMPLETED

Nagoya, Aichi-ken, 453-8511, Japan
Novartis Investigative Site
COMPLETED

Nagoya, Aichi-ken, 464 8681, Japan
Novartis Investigative Site
COMPLETED

Toyohashi, Aichi-ken, 441-8570, Japan
Novartis Investigative Site
COMPLETED

Toyota, Aichi-ken, 470-0343, Japan
Novartis Investigative Site
COMPLETED

Daisen, Akita, 014-0027, Japan
Novartis Investigative Site
RECRUITING

Chiba, Chiba, 260 8677, Japan
Novartis Investigative Site
COMPLETED

Funabashi, Chiba, 273-8588, Japan
Novartis Investigative Site
RECRUITING

Kashiwa, Chiba, 277 8577, Japan
Novartis Investigative Site
RECRUITING

Fukuoka, Fukuoka, 811-1395, Japan
Novartis Investigative Site
RECRUITING

Kurume, Fukuoka, 830-0011, Japan
Novartis Investigative Site
RECRUITING

Fukuyama, Hiroshima, 721-8511, Japan
Novartis Investigative Site
RECRUITING

Sapporo, Hokkaido, 065-0033, Japan
Novartis Investigative Site
RECRUITING

Sapporo, Hokkaido, 608543, Japan
Novartis Investigative Site
COMPLETED

Amagasaki, Hyōgo, 660-8511, Japan
Novartis Investigative Site
COMPLETED

Kobe, Hyōgo, 650-0011, Japan
Novartis Investigative Site
RECRUITING

Kobe, Hyōgo, 6500047, Japan
Novartis Investigative Site
RECRUITING

Mito, Ibaraki, 311-4145, Japan
Novartis Investigative Site
COMPLETED

Morioka, Iwate, 020 0066, Japan
Novartis Investigative Site
RECRUITING

Kagoshima, Kagoshima-ken, 890 8520, Japan
Novartis Investigative Site
RECRUITING

Sagamihara, Kanagawa, 252-0375, Japan
Novartis Investigative Site
RECRUITING

Yokohama, Kanagawa, 245-8575, Japan
Novartis Investigative Site
RECRUITING

Yokohama, Kanagawa-ku, 236-0004, Japan
Novartis Investigative Site
RECRUITING

Kyoto, Kyoto, 602-8566, Japan
Novartis Investigative Site
COMPLETED

Natori-shi, Miyagi, 981-1293, Japan
Novartis Investigative Site
RECRUITING

Sendai, Miyagi, 980 8574, Japan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Iida, Nagano, 395-8502, Japan
Novartis Investigative Site
RECRUITING

Matsumoto, Nagano, 3908621, Japan
Novartis Investigative Site
COMPLETED

Matsumoto, Nagano, 3908621, Japan
Novartis Investigative Site
RECRUITING

Yufu, Oita Prefecture, 8795593, Japan
Novartis Investigative Site
RECRUITING

Okayama, Okayama-ken, 7011192, Japan
Novartis Investigative Site
RECRUITING

Habikino, Osaka, 583-0872, Japan
Novartis Investigative Site
COMPLETED

Izumisano, Osaka, 5988577, Japan
Novartis Investigative Site
RECRUITING

Osaka, Osaka, 5340021, Japan
Novartis Investigative Site
COMPLETED

Osaka, Osaka, 5340021, Japan
Novartis Investigative Site
COMPLETED

Osaka, Osaka, 550-0015, Japan
Novartis Investigative Site
RECRUITING

Takatsuki, Osaka, 5698686, Japan
Novartis Investigative Site
RECRUITING

Kawagoe, Saitama, 350 8550, Japan
Novartis Investigative Site
RECRUITING

Saitama, Saitama, 330 8777, Japan
Novartis Investigative Site
RECRUITING

Sunto Gun, Shizuoka, 411 8777, Japan
Novartis Investigative Site
COMPLETED

Shimotsuke, Tochigi, 329-0498, Japan
Novartis Investigative Site
RECRUITING

Bunkyo Ku, Tokyo, 113 8655, Japan
Novartis Investigative Site
COMPLETED

Bunkyo Ku, Tokyo, 113 8655, Japan
Novartis Investigative Site
COMPLETED

Bunkyo-ku, Tokyo, 113-8603, Japan
Novartis Investigative Site
RECRUITING

Bunkyo-ku, Tokyo, 1138519, Japan
Novartis Investigative Site
COMPLETED

Bunkyo-ku, Tokyo, 1138519, Japan
Novartis Investigative Site
COMPLETED

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site
RECRUITING

Chuo Ku, Tokyo, 104 0045, Japan
Novartis Investigative Site
RECRUITING

Chuo Ku, Tokyo, 104 8560, Japan
Novartis Investigative Site
RECRUITING

Minato-ku, Tokyo, 105-8471, Japan
Novartis Investigative Site
COMPLETED

Minato-ku, Tokyo, 108-8639, Japan
Novartis Investigative Site
RECRUITING

Setagaya-ku, Tokyo, 1578535, Japan
Novartis Investigative Site
COMPLETED

Shibuya City, Tokyo, 150-8308, Japan
Novartis Investigative Site
COMPLETED

Shinjuku Ku, Tokyo, 160-0023, Japan
Novartis Investigative Site
COMPLETED

Shinjuku Ku, Tokyo, 162 8666, Japan
Novartis Investigative Site
RECRUITING

Shinjuku-ku, Tokyo, 160 8582, Japan
Novartis Investigative Site
COMPLETED

Wakayama, Wakayama, 641-8510, Japan
Novartis Investigative Site
RECRUITING

Wakayama, Wakayama, 641-8510, Japan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Yamagata, Yamagata, 990 9585, Japan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Akita, 010-8543, Japan
Novartis Investigative Site
RECRUITING

Fukuoka, 8128582, Japan
Novartis Investigative Site
RECRUITING

Hiroshima, 7348551, Japan
Novartis Investigative Site
RECRUITING

Kochi, 781 8555, Japan
Novartis Investigative Site
RECRUITING

Kyoto, 606 8507, Japan
Novartis Investigative Site
RECRUITING

Okayama, 7008558, Japan
Novartis Investigative Site
COMPLETED

Osaka, 5458586, Japan
Novartis Investigative Site
RECRUITING

Shizuoka, 420 8660, Japan

Conditions

Explore the condition pages connected to this study.

BRAF V600E MUTATION-POSITIVE UNRESECTABLE ADVANCED OR RECURRENT SOLID TUMOR